Good evening :)
$
₹
Exelixis Inc

Exelixis Inc

EXEL

NASDAQ
Asset Logo

Exelixis Inc

EXEL

NASDAQ
$57.950.69% (-0.40)
$
₹
$57.950.69% (-0.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $14.5B the stock is ranked 775

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

18.35
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.83
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$3.18
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.26
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

35.33%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 20 analysts' reports

Buy
10 analysts
Hold
9 analysts
Sell
1 analyst

Analysts expect a -8.21% price downside over the next year

Current Price$57.95
Target Price$53.68

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.56
74.56
1Y Return
19.79%
19.79%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.98
23.98
1Y Return
38.66%
38.66%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.8%
32.8%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.58
29.58
1Y Return
31.31%
31.31%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.41
19.41
1Y Return
31.25%
31.25%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Exelixis Inc 18.357.832.26
AbbVie Inc74.5650.450.54
Amgen Inc23.9817.832.32

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

597.7
193.5
598.6
244.5
610.8
210.4
628.6
212
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue425.22637.17539.54566.75555.44568.26597.75598.66610.81628.69
Net Income37.31226.11117.97139.86159.61184.84193.57244.52210.46212.05
Net Profit Margin8.77%35.48%21.86%24.67%28.73%32.52%32.38%40.84%34.45%33.72%
See CostsAll values in $ Million

Frequently asked questions

  1. Exelixis Inc (EXEL) share price today is $57.95 as of September 21, 2026 at 8:31 PM IST. The stock touched a day high of $58.71 and a day low of $57.91.

  2. Exelixis Inc stock trades on NASDAQ under the ticker symbol EXEL.

  3. Exelixis Inc's market capitalization is $14.46B as of September 21, 2026 at 8:31 PM IST.

  4. Exelixis Inc's price-to-earnings (P/E) ratio is 18.35 as of September 21, 2026.

  5. Exelixis Inc's price-to-book (P/B) ratio is 7.83 as of September 21, 2026.

  6. Yes, You can buy Exelixis Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Exelixis Inc shares in three steps: 1. Search Exelixis Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Exelixis Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Exelixis Inc (EXEL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1725 shares at the current price of $57.95.

Loading...